CooperCompanies Stock Climbs 3.9% Ahead of Q4 Earnings on 6% Growth Forecast
CooperCompanies reported Q3 revenues of $1.07 billion, up 4.6% year on year, and beat analysts’ full-year and next-quarter EPS guidance despite multiple revenue-estimate misses in the past two years. Shares gained 3.9% last month as investors anticipate 6% Q4 revenue growth and a $90.56 average analyst price target.
1. Q3 Financial Results
CooperCompanies reported Q3 revenue of $1.07 billion, marking a 4.6% increase year on year. The company beat analysts’ full-year and next-quarter EPS guidance, reversing a trend of multiple revenue-estimate misses over the past two years.
2. Q4 Revenue Forecast and Analyst Outlook
For Q4, revenue is expected to grow 6% year on year, up from a 3.6% increase in the same quarter last year. Analysts have maintained their estimates over the past month, signaling confidence in the company’s near-term performance.
3. Share Performance and Price Targets
CooperCompanies shares rose 3.9% during the past month, reflecting market optimism ahead of the earnings release. The stock trades near $82.45, with an average analyst price target of $90.56.
4. Peer Sector Performance
Within the diversified medical devices & supplies segment, peers such as Stryker and Boston Scientific reported Q4 revenue growth of 11.4% and 15.9%, respectively. Stryker’s shares gained 4.3% following results, while Boston Scientific’s declined 15.3%, highlighting varied market reactions.